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Abstract
High-dose cyclophosphamide (Cy) is frequently employed for peripheral blood mobilization of 
hematopoietic stem cells before high-dose chemotherapy with autologous stem cell transplantation 
(ASCT) in multiple myeloma (MM). The benefit of mobilization with Cy over filgrastim 
(granulocyte colony-stimulating factor; G-CSF) alone is unclear. Between 2000 and 2008, 167 
patients with newly diagnosed MM underwent single ASCT after melphalan conditioning at our 
institution. Seventy-three patients were mobilized with G-CSF alone, and 94 patients with Cy plus 
G-CSF (Cy+G-CSF). We retrospectively analyzed Cy’s impact on both toxicity and efficacy. 
Mobilization efficiency was augmented by Cy; a mean total of 12 versus 5.8 × 106 CD34+ 
cells/kg were collected from patients mobilized with Cy+G-CSF versus G-CSF, respectively, (P 
<0.01), over a mean of 1.6 versus 2.2 days of peripheral blood apheresis (p = 0.001). 
Mobilization-related toxicity was also, however, augmented by Cy; 14% of Cy+G-CSF patients 
were hospitalized because of complications versus none receiving G-CSF (P <0.0001). Toxicity, 
including death, related to ASCT was similar between cohorts. Regarding long-term outcomes, 
multivariate analysis revealed no difference for Cy+G-CSF versus G-CSF (hazard ratio 0.8 for 
event-free survival [95% confidence interval {CI} 0.57–1.25] and 0.96 for overall survival [95% 
CI 0.61–1.54]). In summary, we show that mobilization with Cy increases toxicity without 
positively impacting long-term outcomes in MM. Our findings place into question Cy’s benefit as 
a routine component of stem cell mobilization regimens in MM. Randomized trials are needed to 
elucidate the risks and benefits of Cy more definitively.
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High-dose chemotherapy with autologous peripheral blood hematopoietic stem cell 
transplantation (ASCT) is a standard treatment approach for fit patients with multiple 
myeloma (MM) [1]. The optimal mobilization regimen for collection of stem cells via 
peripheral blood is still a matter of debate. High-dose cyclophosphamide (Cy) causes the 
release of proteases and the cleavage of key adhesion molecules, such as vascular cell 
adhesion molecule-1 (VCAM-1) and C-X-C chemokine receptor type 4 (CXCR4), 
culminating in the release of hematopoietic stem cells into the peripheral blood [2,3]. Cy-
based mobilization remains in common use since its inception nearly two decades ago [4], 
but growth factors such as filgrastim (granulocyte colony-stimulating factor; G-CSF) have 
also been shown to successfully mobilize stem cells without Cy’s toxicity [5–13]. Newer 
MM therapies such as lenalidomide impair stem cell collection [14] and the finding that 
patients treated with lenalidomide can often be mobilized with the addition of Cy [15,16] 
amplified the necessity for Cy in recent years. Countering that more recently, however, is 
the introduction of the pricey yet efficacious CXCR4 antagonist plerixafor, which can 
mobilize even lenalidomide-treated patients [17,18]. Cy’s role in mobilization is therefore 
murky but the question is important; many MM patients receive not one but two ASCTs as 
part of their MM care (either back-to-back as tandem ASCT, or early and again later over 
their years of MM therapy), and so adequate stem cell collection for not one but two ASCTs 
is generally held as the goal for any mobilization program. Efficient and safe mobilization is 
critical.
Aside from its capacity to mobilize, Cy’s popularity also stems from its cytotoxicity, which 
carries the allure of “debulking” MM during stem cell collection. Retrospective studies, 
however, have shown that Cy does not impact survival [19,20], which suggests that Cy’s 
theoretical anti-MM effects during mobilization are clinically irrelevant. Published data are 
still very limited, so we undertook a retrospective analysis of our own consecutively treated, 
newly diagnosed MM patients with long-term follow-up, who underwent a single ASCT 
following melphalan conditioning at our institution, after mobilization with either Cy plus 
G-CSF (Cy+G-CSF) or G-CSF alone.
MATERIALS AND METHODS
Patients and Study Design
We retrospectively interrogated a prospectively maintained clinical database of transplant 
patients at our institution and reviewed individual charts for adult patients with MM who 
underwent peripheral blood stem cell collection followed by ASCT at Duke Cancer Institute 
between 2001 and 2008. We excluded patients who: carried a second, concurrent 
malignancy (e.g., non-Hodgkin’s lymphoma) or plasma cell leukemia; received either 
tandem ASCT or their first ASCT not as part of initial therapy (defined as first ASCT ≥2 
years after diagnosis of active MM); received plerixafor or etoposide as part of their 
mobilization regimen; or received regimen other than single-agent melphalan as 
conditioning. Institutional review board (IRB) approval at Duke University Medical Center 
was obtained before study initiation.
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Mobilization and Transplant Procedures
Mobilization regimens were chosen purely according to physician discretion. G-CSF 
patients were mobilized with single agent G-CSF (filgrastim) 10 μg/kg subcutaneously (SC) 
for 5 days, while patients in the Cy+G-CSF arm received Cy 3–4 gm/m2 intravenously (IV) 
4 days before initiation of G-CSF 10 μg/kg/day SC, which was given until stem cell 
collection. Collection was performed the day the white blood cell count (WBC) recovered to 
≥5,000/μl. The minimum required cell collection was 2 × 106 CD34+ cells/kg, while the 
target collection was 8–10 × 106 CD34+ cells/kg. Within 2 weeks of stem cell collection, on 
day 1, most patients received a single dose of intravenous melphalan 200 mg/m2. Patients 
over age 70 or with impaired renal function (defined as a calculated creatinine clearance of 
<50 ml/min) received dose-reduced melphalan at 140 mg/m2 as standard practice. On day 0, 
half of the collected cells, with a minimum of 2 × 106 CD34+/kg, were reinfused. Patients 
received G-CSF support (5 μg/kg/day SC) following cell infusion until engraftment. 
Maintenance therapy was defined as initiation of therapy at any time post-ASCT without 
clinical or serological evidence of relapsed/progressive MM. Multi-agent consolidation 
regimens were almost never employed in this patient cohort.
Engraftment, Toxicity, and Response Assessment
Engraftment was defined by transfusion-independent platelet levels ≥20,000/μl, and G-CSF-
independent absolute neutrophil count >500/μl, each for at least three consecutive days. 
Objective response to therapy was assessed using standard International Myeloma Working 
Group criteria [21]. Both overall survival (OS) and event-free survival (EFS) were 
calculated from day of stem cell reinfusion (day 0). OS was defined as death by any cause. 
Missing OS data in the clinical records were ascertained by accessing the Social Security 
Death Index. EFS was defined as time to relapse or progression according to standard 
definitions [21] or death. Treatment-related mortality was defined as death not related to 
disease relapse within 6 months of ASCT. Toxicity was assessed qualitatively and with a 
focus on need for hospitalization in order to reduce imprecision that could arise from 
retrospectively grading mild to moderate toxic events based on chart review.
Statistical Analysis
Patient data through November 1, 2013 were analyzed. Subjects who were free of events 
then were censored as of that date. We employed chi-square and Fisher’s exact test to 
compare differences between nominal variables, and Mann–Whitney tests for continuous 
variables. Correction for multiple testing was not performed in this exploratory analysis. For 
OS and EFS, we plotted Kaplan–Meier survival curves and used the log-rank test to test 
differences between the two groups. We fitted a proportional hazards model to test the 
difference in OS and EFS between the two groups, while controlling for confounding 
variables. Two-way analysis of variance (ANOVA) was performed to test the impact of 
mobilization regimen and pretransplant depth of response (dichotomized as very good 
partial response [VGPR] vs. partial response [PR] or worse) on stem cell collection yield, 
including testing for interaction. All analyses were performed using GraphPad Prism 5 v5.04 
for nominal and categorical variables, and R for Kaplan-Meier time-to-event, ANOVA, and 
multivariate analyses.
Tuchman et al. Page 3














Patient and Treatment Characteristics
One hundred eighty-six patients were initially identified in the database as potential subjects 
for this study. Nineteen patients were excluded on chart review primarily due to a 
synchronous malignancy or tandem ASCT. Ultimately 94 subjects were included who had 
received Cy+G-CSF, whereas 73 had received G-CSF alone. Toxicity data from 17 patients 
have been reported as part of a prior study by members of our group [13]. There were no 
significant differences between groups in age, gender, immunoglobulin subtype, or 
premobilization assessments of International Staging System (ISS) stage [22] (Table I), 
serum creatinine, or hemoglobin (data not shown). Cy+G-CSF versus G-CSF use varied 
somewhat by year, ranging without a clear trend from 27.3% of subjects receiving Cy-G-
CSF in 2006 to 85.3% in 2003. Table II shows that induction regimens varied widely based 
on employment of novel agents and need for salvage induction regimens (>1 line of 
therapy). Although overall response rate (ORR) after induction was similar between groups, 
VGPR or better was seen in 23% of patients mobilized with Cy+G-CSF in comparison to 
41% of those who received G-CSF (P = 0.02). Median time between diagnosis and ASCT 
was 8.6 months for Cy+G-CSF and 7.7 months for G-CSF (P = 0.23). For ASCT, high-dose 
melphalan was dose-reduced from the standard 200 mg/m2 in similar numbers of patients 
from each group and after ASCT, more Cy+G-CSF patients received maintenance therapy.
Stem Cell Collection, Toxicity, and Engraftment
Stem cell collection was enhanced by Cy, with mean total collection of 12 versus 5.8 × 106 
CD34+ cells/kg from patients mobilized with Cy+G-CSF vs. G-CSF, respectively (P <0.01). 
Premobilization depth of response did not affect collection ((P = 0.18). Testing for 
interaction between mobilization regimen and pre-mobilization depth of response was not 
statistically significant (P = 0.27). Cy+G-CSF also shortened number of days required for 
apheresis to 1.6 days from 2.2 days for subjects on G-CSF (P = 0.001). Toxicity and 
engraftment data are tabulated in Table III. During mobilization, mild myalgias were 
commonly noted in G-CSF-mobilized patients (data not shown) but no serious adverse 
events were observed. Conversely, many Cy+G-CSF patients experienced toxicity, 
culminating in a 14% rate of hospitalization. Once patients advanced to ASCT, the incidence 
of specific toxicities was similar. Our center routinely performs ASCT in an outpatient 
clinic, and hospitalization rates during ASCT were comparable as was treatment-related 
mortality between the two groups. Platelet engraftment was slower in G-CSF-mobilized 
patients, whereas median time until neutrophil engraftment was statistically equivalent.
Response to Transplant and Predictors of Remission and Survival
Objective responses post-ASCT are summarized in Table III and were similar between 
groups, as were OS and EFS (Figs 1 and 2, respectively). Given the variability in induction 
regimens and premobilization depth of response, we performed multivariate analysis in an 
effort to dissect the effect of confounders from Cy’s effect on long-term endpoints. As 
shown in Table IV, the only predictor of longer EFS was the premobilization achievement of 
VGPR or better, whereas VGPR or better and ISS stage I or II both predicted longer OS. 
Abnormalities in cytogenetics or fluorescent in situ hybridization (FISH), employment of 
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novel agents with induction, maintenance therapy, and Cy all were all insignificant 
predictors of outcomes.
DISCUSSION
ASCT remains a standard of care for MM, prolonging remission and in some studies OS as 
compared with conventional chemotherapy [1,23–25]. Contemporary MM treatment often 
includes not one but two ASCTs over the course of any given patient’s treatment course. 
Hence stem cell mobilization strategies are generally aimed at collecting enough stem cells 
for two ASCTs. Effective mobilization is critical.
Cy’s popularity as a component of mobilization regimens has increased in recent years 
because of its capacity to augment stem cell collection [4–12], which is especially relevant 
for patients treated with lenalidomide [14–16]. Additionally Cy theoretically adds an anti-
MM effect to mobilization programs. Countering those advantages is Cy’s more severe 
toxicity profile compared with G-CSF alone. It is hence vital to determine whether Cy’s 
benefits truly merit the toxicity particularly with the availability of plerixafor, which is 
expensive but can salvage collection in patients who fail G-CSF mobilization, and without 
Cy’s toxicity [17.]
In this study, we report our retrospective institutional experience of using Cy+G-CSF vs. G-
CSF mobilization in patients with MM undergoing melphalan conditioning and single ASCT 
for newly diagnosed MM. First, we confirm that Cy enhances mobilization, with Cy+G-CSF 
mobilized patients yielding more than twice as many CD34+ cells as G-CSF mobilized 
patients over a smaller number of days of apheresis. However, toxicity related to 
mobilization was markedly higher in the group that received Cy+G-CSF as well, with 14% 
of patients requiring hospitalization versus no patients who received G-CSF. ASCT was 
completed with similar toxicity and efficacy in both groups. Long-term, Cy had no 
observable effect on EFS or OS in unadjusted and multivariate analyses. In fact, the only 
predictors of EFS or OS were premobilization achievement of VGPR or better (for both), 
and ISS stage (for OS alone).
Our findings add important evidence to and are concordant with the limited literature that 
exists on this topic. Dingli et al., published a similar study [19], updated later [6], in which 
they saw no change in progression-free survival or OS with Cy+G-CSF vs. G-CSF. A report 
by Nakasone et al., also demonstrated no benefit to Cy [20]. Directly comparing 
retrospective studies is of course fraught with challenges, but now multiple studies 
demonstrating the same effect increase the credibility of this finding as a whole.
Limitations in our report merit discussion and shed light on our findings. First, this is a 
nonrandomized, retrospective study, and as such it is susceptible to the usual biases and 
confounders such as selection bias. Second, pre-ASCT and post-ASCT treatment was 
heterogeneous. Before ASCT, twice the percentage of G-CSF patients received bortezomib 
when compared with Cy+G-CSF patients. The potential implications of that discrepancy on 
long-term survival are complex. Given clear data that bortezomib prolongs survival [26]. 
one would expect the inclusion of bortezomib to benefit OS. However, many patients 
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studied here received initial conventional chemotherapy such as vincristine, doxorubicin, 
and dexamethasone (VAD), with bortezomib only employed as second-line therapy for 
inadequate responses; that could easily transform bortezomib usage into a potential predictor 
of poorer OS. As for Cy, Cy+G-CSF patients tended to have less deep pre-mobilization 
response, and they also more frequently received post-ASCT maintenance therapy. 
Conversely, fitter patients are also sometimes preferentially administered Cy because of 
increased perceived likelihood of tolerating it. Such confounders and biases could be quite 
mixed in their positive or negative effects on outcome in each patient cohort. It is perhaps 
therefore unsurprising that employment of neither Cy nor bortezomib predicted EFS or OS 
even in multivariate analysis. Last, although we were able to comment on whether any 
cytogenetic or FISH abnormalities were present in most subjects premobilization (a known 
prognostic factor in and of itself [27]), we lacked information for the majority of patients on 
the specific nature of those abnormalities, and hence, certain key prognostic markers could 
not be evaluated as part of this study.
In terms of generalizability, the MM literature is dogged by a constant battle between 
obsolete therapies and adequate follow-up. Truly discerning the benefit of any regimen is 
contingent on long-term follow-up of hard endpoints such as duration of remission and 
overall survival. Median survival in myeloma is now multiple years [28,29], which means 
that trials will often take years to detect differences in those endpoints and by the time 
differences become evident, the regimens are obsolete. One strength of our study is that we 
designed it to strike a balance between those two competing interests. We included only 
patients transplanted between 2001 and 2008 to capture a population that had largely 
received novel agents in induction. We excluded more recently transplanted patients so as to 
mostly avoid those who had received maintenance therapy, which would be a significant 
confounder, as well as patients with immature follow-up.
Taken together, our retrospective data demonstrate that mobilizing MM patients with Cy in 
preparation for ASCT increases collection efficiency but has no clear benefit on long-term 
outcomes, including survival, despite markedly increasing mobilization-associated toxicity. 
These data add important additional evidence to the currently limited literature that shows 
little benefit to Cy, particularly nowadays when even patients who are difficult to mobilize 
using G-CSF alone can be salvaged with plerixafor. Our findings further call into question 
the need for Cy as a routine component in mobilization strategies. Ultimately, a randomized 
controlled trial is needed to answer this important question once and for all. Currently, we 
know of no such study being planned.
CONCLUSIONS
Adding Cy to hematopoietic stem cell mobilization regimens for MM before ASCT 
enhances stem cell collection but adds toxicity with no clear benefit on long-term outcomes. 
Prospective, randomized trials are warranted to definitely elucidate risk versus benefit, but 
for now, the routine employment of Cy should be carefully considered if not avoided in 
many cases.
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TABLE I
Patient and MM Pretransplant Characteristics
Cy+G-CSF (n = 94) G-CSF (n = 73) P-value
Female gender, % 35 44 0.27
Median age at ASCT, years (range) 59 (34–76) 57 (33–73) 0.19
MM subtype, % 0.63
IgG 62 64
IgA 22 21
Light chain 14 15
Other 1 0









Totals of percentages may not equal 100% due to rounding.
ISS = International Staging System.
a
Unknown subjects were excluded from statistical analysis.
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TABLE II
Data Regarding Therapy
Cy+G-CSF (n = 94) G-CSF (n = 73) P-value
Pre-ASCT induction regimen, %
 Included thalidomide or lenalidomide 40 38 0.87
 Included bortezomib 23 48 0.001
Multiple regimens (i.e., required salvage) 27 25 0.85
Response to induction (pre-ASCT), %
 Overall response rate (PR or better) 92 99 0.11
 VGPR or better 23 41 0.02
  CR 5 7
  VGPR 18 34
  PR 67 56
  <PR 7 1
  Unknowna 1 0
Melphalan dose for ASCT conditioning, %
 200 mg/m2 91 84 0.32b
 140 mg/m2 9 14
Received maintenance thalidomide or lenalidomide, % 14 3 0.01
Totals of percentages may not equal 100% due to rounding.
a
Counted as no response (<PR) for statistical analysis.
b
Fisher’s exact test of full versus reduced dose melphalan.
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TABLE III
Data regarding Toxicity, Engraftment, and Post-Transplant Response
Cy+G-CSF (n = 94) G-CSF (n = 73) P-value
Toxicity related to mobilization (%)
 Febrile neutropenia 23 0 <0.0001
 Hematuria (hemorrhagic cystitis) 8 0 <0.0001
Toxicity requiring hospitalization (%) 14 0 <0.0001
Toxicity related to ASCT (%)
 Febrile neutropenia 70 68 0.87
 Pneumonitis 14 16 0.66
Toxicity requiring hospitalization (%) 31 38 0.33
Treatment-related mortality (%) 4 1 0.39
Median time to neutrophil engraftment, days (range) 11 (9–15) 11 (9–23) 0.4
Median time to platelet engraftment, days (range) 13(10–21) 14 (9–31) 0.007
Response after ASCT, %
 Overall response rate (PR or better) 94 94 1
 VGPR or better 44 58 0.11
  CR 5 7
  VGPR 39 51
  PR 49 36
  <PR 1 1
  Unknown or treatment-related mortality 5 5
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